Nebulized furosemide as adjunctive therapy in patients with stable chronic obstructive pulmonary disease : A randomized controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202106917652038

Enrollment

100

Registered

2021-06-17

Start date

2021-07-01

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory

Interventions

Nebulized furosemide

Nebulized normal saline

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Stable (Not exacerbating) COPD patients documented by the pulmonologist - FEV1, FVC, (FEV1/FVC) less than 70% - Irreversible response to inhaled ß-agonist (FEV1i ncrease <12% and <200 cc after15min from baseline) - Symptoms last about 5 years of breathlessness and, productive cough

Exclusion criteria

Exclusion criteria: Patients with history of other lung diseases such as pneumonia, idiopathic pulmonary fibrosis, consolidation, congestive heart failure, exacerbated, asthma or asthma-COPD overlap. Smoking more than 15 packs/year using furosemide and other diuretics

Design outcomes

Primary

Measure	Time frame
forced expiratory volume/second (FEV1) ;Forced vital capacity (FVC);FEV1/FVC	—

Secondary

Measure	Time frame
Modified Medical Research Council (mMRC) ;COPD assessment test (CAT)	—

Countries

Egypt

Contacts

Public ContactElsayedamr Basma

Patient Information Manager

elsayedamr@yahoo.com00201223106023

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026